Browse by Medical Category
Accepting New Patients
Matthew Smith, M.D., Ph.D. is the Director of the Genitourinary Malignancies Program at the Massachusetts General Hospital Cancer Center. His clinical practice and research program focus on the management of prostate cancer.
Go To Programs
Go To Programs
Go To Specialties
Dr. Matthew R. Smith is Director of the Genitourinary Oncology Program at Massachusetts General Hospital Cancer Center and an Associate Professor of Medicine at Harvard Medical School.He graduated summa cum laude from Canisius College with a B.A. in biochemistry. He received his MD and PhD degrees from Duke University School of Medicine. He trained in Internal Medicine at Brigham and Women's Hospital.He completed a fellowship in Medical Oncology at Dana Farber Cancer Institute and a postdoctoral fellowship at Massachusetts Institute of Technology.He is an internationally recognized expert in prostate cancer. He has published extensively on treatment and prevention of bone metastases and prostate cancer survivorship. He has authored more than 150 peer-reviewed articles including manuscripts in New England Journal of Medicine, Journal of Clinical Oncology, Cancer, Journal of Clinical Endocrinology and Metabolism, and Clinical Cancer Research. His research is supported by competitive grants and awards from the National Institutes of Health, Lance Armstrong Foundation Research Award, and the Prostate Cancer Foundation.
View my most recent publications at PubMed
An international clinical trial has found that treatment with a drug that suppresses the normal breakdown of bone can delay the development of bone metastases in men with prostate cancer.
Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, led a study on a new targeted therapy to stop bone loss, increase bone density and prevent spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.
Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.
Back to Top